Molecular_JJ
basis_NN
of_IN
a_DT
multiple_JJ
lymphokine_NN
deficiency_NN
in_IN
a_DT
patient_NN
with_IN
severe_JJ
combined_JJ
immunodeficiency_NN
._.

We_PRP
have_VBP
previously_RB
reported_VBN
that_IN
the_DT
T_NN
lymphocytes_NNS
of_IN
a_DT
child_NN
with_IN
severe_JJ
combined_JJ
immunodeficiency_NN
are_VBP
defective_JJ
in_IN
the_DT
transcription_NN
of_IN
several_JJ
lymphokine_NN
genes_NNS
that_WDT
include_VBP
IL2_NN
,_,
IL3_NN
,_,
IL4_NN
,_,
and_CC
IL5_NN
,_,
which_WDT
encode_VBP
interleukins_NNS
2_CD
,_,
3_CD
,_,
4_CD
,_,
and_CC
5_CD
-LRB-_-LRB-
IL-2_NN
,_,
-3_CD
,_,
-4_CD
,_,
and_CC
-5_CD
-RRB-_-RRB-
._.

To_TO
determine_VB
whether_IN
the_DT
defect_NN
in_IN
the_DT
patient_NN
's_POS
T_NN
lymphocytes_NNS
involved_VBD
a_DT
trans-acting_JJ
factor_NN
common_JJ
to_TO
the_DT
affected_VBN
lymphokine_NN
genes_NNS
,_,
we_PRP
examined_VBD
the_DT
ability_NN
of_IN
nuclear_JJ
factors_NNS
from_IN
the_DT
patient_NN
's_POS
T_NN
lymphocytes_NNS
to_TO
bind_VB
response_NN
elements_NNS
present_JJ
in_IN
the_DT
regulatory_JJ
region_NN
of_IN
IL2_NN
._.

Nuclear_JJ
factor_NN
NF-kB_NN
,_,
activation_NN
protein_NN
1_CD
-LRB-_-LRB-
AP-1_NN
-RRB-_-RRB-
,_,
OCT-1_NN
,_,
and_CC
NF-IL-2B_NN
binding_NN
activity_NN
were_VBD
normal_JJ
._.

In_IN
contrast_NN
,_,
the_DT
binding_NN
of_IN
the_DT
nuclear_JJ
factor_NN
of_IN
activated_VBN
T_NN
cells_NNS
-LRB-_-LRB-
NF-AT_NN
-RRB-_-RRB-
to_TO
its_PRP$
response_NN
element_NN
in_IN
the_DT
IL2_NN
enhancer_NN
and_CC
to_TO
an_DT
NF-AT-like_JJ
response_NN
element_NN
present_JJ
in_IN
the_DT
IL4_NN
enhancer_NN
was_VBD
abnormal_JJ
._.

To_TO
ascertain_VB
whether_IN
the_DT
abnormal_JJ
NF-AT_NN
binding_NN
activity_NN
was_VBD
related_JJ
to_TO
an_DT
impaired_JJ
function_NN
,_,
we_PRP
transfected_VBD
patient_NN
and_CC
control_NN
T_NN
lymphocytes_NNS
with_IN
constructs_NNS
containing_VBG
the_DT
reporter_NN
gene_NN
encoding_VBG
chloramphenicol_NN
acetyl_NN
transferase_NN
-LRB-_-LRB-
CAT_NN
-RRB-_-RRB-
under_IN
the_DT
control_NN
of_IN
the_DT
entire_JJ
IL2_NN
regulatory_JJ
region_NN
or_CC
of_IN
multimers_NNS
of_IN
individual_JJ
enhancer_NN
sequences_NNS
._.

CAT_NN
expression_NN
directed_VBN
by_IN
the_DT
IL2_NN
regulatory_JJ
region_NN
or_CC
by_IN
a_DT
multimer_NN
of_IN
the_DT
NF-AT-binding_JJ
site_NN
was_VBD
markedly_RB
lower_JJR
in_IN
the_DT
patient_NN
relative_JJ
to_TO
controls_NNS
._.

In_IN
contrast_NN
,_,
CAT_NN
gene_NN
expression_NN
directed_VBN
by_IN
a_DT
multimer_NN
of_IN
the_DT
OCT-1_NN
proximal_NN
-LRB-_-LRB-
OCT-1p_NN
-RRB-_-RRB-
-_:
binding_NN
site_NN
was_VBD
equivalent_JJ
in_IN
patient_NN
and_CC
controls_NNS
._.

These_DT
results_NNS
indicate_VBP
that_IN
an_DT
abnormality_NN
of_IN
\/_NN
or_CC
influencing_JJ
NF-AT_NN
may_MD
underlie_VB
the_DT
multiple_JJ
lymphokine_NN
deficiency_NN
in_IN
this_DT
patient_NN

